Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 61 results for cataracts

  1. Ab interno canaloplasty for open-angle glaucoma (HTG647)

    Evidence-based recommendations on ab interno canaloplasty for open-angle glaucoma. This involves widening the channel that drains fluid from the eye. The aim is to reduce pressure in the eye.

  2. Sunlight exposure: risks and benefits (NG34)

    This guideline covers how to communicate the risks and benefits of natural sunlight exposure (specifically, the ultraviolet rays UVA and UVB) to help people understand why they may need to modify their behaviour to reduce their risk of skin cancer and vitamin D deficiency.

  3. Omalizumab for treating severe persistent allergic asthma (TA278)

    Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.

  4. Falls (QS86)

    This quality standard covers prevention of falls and assessment after a fall in people who are living in the community, in a residential care setting or staying in hospital and are:

  5. Limited macular translocation for wet age-related macular degeneration (HTG215)

    Evidence-based recommendations on limited macular translocation for wet age related macular degeneration. This involves cutting and moving the macula on an a nearby healthier area of the retina.

  6. Photorefractive (laser) surgery for the correction of refractive errors (HTG107)

    Evidence-based recommendations on photorefractive (laser) surgery for the correction of refractive errors. This involves using a special laser to permanently change the shape of the cornea.

  7. Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)

    Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women.

  8. Interventions to manage cystoid macular oedema:- What is the most effective postoperative medical management for cystoid macular oedema?

    oedema. Source guidance details Comes from guidance Cataracts in adults: management Number NG77 Date issued October

  9. Insertion of an epiretinal prosthesis for retinitis pigmentosa (HTG372)

    Evidence-based recommendations on insertion of an epiretinal prosthesis for retinitis pigmentosa. This involves inserting an implant into the eye that receives data from a small camera on the person's glasses and then stimulates healthy cells in the retina to see basic images.

  10. Brain tumours (primary) and brain metastases in over 16s (QS203)

    This quality standard covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in adults (aged 16 or over). It describes high-quality care in priority areas for improvement.

  11. Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (TA305)

    Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by macular oedema from central retinal vein occlusion in adults.

  12. Prioritisation board decisions 2025

    Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

  13. Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)

    Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.

  14. Implantation of accommodating intraocular lenses for cataract (IPG209)

    We have moved interventional procedures guidance 209 to become HealthTech guidance 134. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.